MeiraGTx (MGTX) Competitors $7.49 +0.05 (+0.67%) Closing price 04:00 PM EasternExtended Trading$7.48 -0.01 (-0.13%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGTX vs. GMTX, RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, TARS, and OCULShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), Tarsus Pharmaceuticals (TARS), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. MeiraGTx vs. Its Competitors Gemini Therapeutics Recursion Pharmaceuticals Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Organon & Co. Alvotech Centessa Pharmaceuticals ImmunityBio Tarsus Pharmaceuticals Ocular Therapeutix MeiraGTx (NASDAQ:MGTX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Is MGTX or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -415.39%. Gemini Therapeutics' return on equity of -38.78% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets MeiraGTx-415.39% -314.44% -63.28% Gemini Therapeutics N/A -38.78%-35.88% Which has more volatility and risk, MGTX or GMTX? MeiraGTx has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Does the media refer more to MGTX or GMTX? In the previous week, MeiraGTx had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for MeiraGTx and 0 mentions for Gemini Therapeutics. MeiraGTx's average media sentiment score of 1.84 beat Gemini Therapeutics' score of 0.75 indicating that MeiraGTx is being referred to more favorably in the media. Company Overall Sentiment MeiraGTx Very Positive Gemini Therapeutics Positive Do insiders and institutionals hold more shares of MGTX or GMTX? 67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 7.5% of MeiraGTx shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer MGTX or GMTX? MeiraGTx currently has a consensus price target of $24.00, suggesting a potential upside of 220.43%. Given MeiraGTx's stronger consensus rating and higher probable upside, equities analysts clearly believe MeiraGTx is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, MGTX or GMTX? Gemini Therapeutics has lower revenue, but higher earnings than MeiraGTx. Gemini Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeiraGTx$33.28M18.11-$147.79M-$2.04-3.67Gemini TherapeuticsN/AN/A-$71.87M-$1.00-59.95 SummaryMeiraGTx beats Gemini Therapeutics on 8 of the 15 factors compared between the two stocks. Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$598.53M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-3.6721.0831.2626.59Price / Sales18.11400.78464.64173.43Price / CashN/A44.6737.7359.36Price / Book187.258.0910.046.68Net Income-$147.79M-$54.08M$3.27B$265.59M7 Day Performance-4.59%2.25%3.17%3.42%1 Month Performance-8.99%3.41%4.34%1.09%1 Year Performance82.24%18.61%44.12%23.84% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.6313 of 5 stars$7.49+0.7%$24.00+220.4%+81.9%$598.53M$33.28M-3.67300News CoveragePositive NewsGap UpGMTXGemini TherapeuticsN/A$59.86-1.4%N/A+20.2%$2.59BN/A-59.8630News CoverageRXRXRecursion Pharmaceuticals1.9803 of 5 stars$5.52-4.3%$7.00+26.8%-35.7%$2.51B$58.84M-3.10400CPRXCatalyst Pharmaceuticals4.8524 of 5 stars$20.23flat$33.20+64.1%-1.4%$2.48B$491.73M12.2680Positive NewsInsider TradeKNSAKiniksa Pharmaceuticals International2.4181 of 5 stars$33.72+1.0%$41.17+22.1%+24.5%$2.47B$423.24M843.21220OGNOrganon & Co.4.8006 of 5 stars$9.27-1.8%$18.00+94.2%-58.9%$2.45B$6.40B3.454,000Positive NewsALVOAlvotech2.0116 of 5 stars$9.00+12.2%$14.00+55.6%-31.5%$2.42B$491.98M39.131,032High Trading VolumeCNTACentessa Pharmaceuticals2.4804 of 5 stars$17.59-2.5%$28.10+59.7%+23.3%$2.42B$6.85M-9.83200IBRXImmunityBio2.251 of 5 stars$2.43-4.7%$10.75+342.4%-44.2%$2.41B$14.74M-5.06590News CoverageAnalyst ForecastTARSTarsus Pharmaceuticals1.8276 of 5 stars$54.61+0.7%$66.67+22.1%+114.2%$2.29B$182.95M-23.4450Positive NewsOCULOcular Therapeutix4.0096 of 5 stars$12.31-2.5%$17.20+39.7%+36.3%$2.20B$63.72M-9.62230Insider Trade Related Companies and Tools Related Companies GMTX Competitors RXRX Competitors CPRX Competitors KNSA Competitors OGN Competitors ALVO Competitors CNTA Competitors IBRX Competitors TARS Competitors OCUL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGTX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access